{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:19:15Z","timestamp":1793841555809,"version":"4.6.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ijantimicag.2022.106532","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T03:08:28Z","timestamp":1643166508000},"page":"106532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Ciprofloxacin resistances rates in Escherichia coli across Canada (CREAC): a longitudinal analysis 2015\u20132019"],"prefix":"10.1016","volume":"59","author":[{"given":"Dylan","family":"Dobbyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teagan","family":"Zeggil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Kudrowich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5095-8570","authenticated-orcid":false,"given":"Nathan P.","family":"Beahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2022.106532_bib0001","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","article-title":"Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success","volume":"22","author":"Redgrave","year":"2014","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.ijantimicag.2022.106532_bib0002","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1155\/2014\/537948","article-title":"Longitudinal surveillance of outpatient \u03b2-lactam antimicrobial use in Canada 1995 to 2010","volume":"25","author":"Glass-Kaastra","year":"2014","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2022.106532_bib0003","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/jac\/dkq225","article-title":"A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000\u201306)","volume":"65","author":"Glass","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106532_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/976273","article-title":"Global fluoroquinolone resistance epidemiology and implications for clinical use","volume":"2012","author":"Dalhoff","year":"2012","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106532_bib0005","series-title":"FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together","year":"2016"},{"key":"10.1016\/j.ijantimicag.2022.106532_bib0006","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1715163517723036","article-title":"The assessment and management of urinary tract infections in adults: guidelines for pharmacists","volume":"150","author":"Beahm","year":"2017","journal-title":"Can Pharm J (Ott)"},{"key":"10.1016\/j.ijantimicag.2022.106532_bib0007","series-title":"Fluoroquinolone prescribing and use in Canadian primary care practice. CADTH Technology Review","author":"Crain","year":"2017"},{"key":"10.1016\/j.ijantimicag.2022.106532_bib0008","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106532_bib0009","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1310\/hpj4804-295","article-title":"Comparison of hospitalwide and custom antibiograms for clinical isolates of Pseudomonas aeruginosa","volume":"48","author":"Bosso","year":"2013","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.ijantimicag.2022.106532_bib0010","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jpids\/pis055","article-title":"Clinical value of an ambulatory-based antibiogram for uropathogens in children","volume":"1","author":"Dahle","year":"2012","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.ijantimicag.2022.106532_bib0011","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.diagmicrobio.2008.12.016","article-title":"Usefulness of antibiogram surveillance for methicillin-resistant Staphylococcus aureus in outpatient pediatric populations","volume":"64","author":"McGregor","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.ijantimicag.2022.106532_bib0012","doi-asserted-by":"crossref","first-page":"i39","DOI":"10.1093\/jac\/dkt025","article-title":"Changes in fluoroquinolone resistance over 5 years (CANWARD 2007\u201311) in bacterial pathogens isolated in Canadian hospitals","volume":"68","author":"Karlowsky","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106532_bib0013","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/ageing\/29.4.297","article-title":"Urinary tract infection in old age: over-diagnosed and over-treated","volume":"29","author":"McMurdo","year":"2000","journal-title":"Age Aging"},{"key":"10.1016\/j.ijantimicag.2022.106532_bib0014","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00002512-200320040-00005","article-title":"Fluoroquinolones in the elderly: safety considerations","volume":"20","author":"Stahlmann","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ijantimicag.2022.106532_bib0015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.diagmicrobio.2016.04.022","article-title":"Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010\u20132014","volume":"85","author":"Lob","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.ijantimicag.2022.106532_bib0016","doi-asserted-by":"crossref","first-page":"iv22","DOI":"10.1093\/jac\/dkz284","article-title":"Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007\u201316","volume":"74","author":"Lagac\u00e9-Wiens","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106532_bib0017","series-title":"Human antimicrobial use report \u20132014 \u2013 Physician diagnosis data","year":"2015"},{"key":"10.1016\/j.ijantimicag.2022.106532_bib0018","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/AAC.44.4.1089-1092.2000","article-title":"A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim\u2013sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group","volume":"44","author":"Zhanel","year":"2000","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485792200022X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485792200022X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:26:42Z","timestamp":1741346802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485792200022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S092485792200022X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106532","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ciprofloxacin resistances rates in Escherichia coli across Canada (CREAC): a longitudinal analysis 2015\u20132019","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106532"}}